Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

CStone Pharmaceuticals

DB:PH4
Snowflake Description

Mediocre balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PH4
DB
HK$8B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The last earnings update was 196 days ago. More info.


Add to Portfolio Compare Print
  • CStone Pharmaceuticals has significant price volatility in the past 3 months.
PH4 Share Price and Events
7 Day Returns
5.3%
DB:PH4
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:PH4
-7.4%
DE Biotechs
-14.2%
DE Market
PH4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CStone Pharmaceuticals (PH4) 5.3% -9.1% -9.1% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on PH4.
  • No trading data on PH4.
Price Volatility
Industry
5yr Volatility vs Market

PH4 Value

 Is CStone Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CStone Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CStone Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CStone Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PH4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CNY CN¥-2.72
SEHK:2616 Share Price ** SEHK (2020-04-08) in HKD HK$8.13
SEHK:2616 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥7.41
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CStone Pharmaceuticals.

DB:PH4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:2616 Share Price ÷ EPS (both in CNY)

= 7.41 ÷ -2.72

-2.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CStone Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CStone Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CStone Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:PH4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-13.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CStone Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CStone Pharmaceuticals's assets?
Raw Data
DB:PH4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CNY CN¥3.31
SEHK:2616 Share Price * SEHK (2020-04-08) in HKD HK$8.13
SEHK:2616 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.911 CN¥7.41
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:PH4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:2616 Share Price ÷ Book Value per Share (both in CNY)

= 7.41 ÷ 3.31

2.24x

* Primary Listing of CStone Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CStone Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CStone Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CStone Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PH4 Future Performance

 How is CStone Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CStone Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare CStone Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CStone Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CStone Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PH4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PH4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -13.7%
DB:PH4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 86.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PH4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PH4 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 541 -2,820 -2,160 2
2021-12-31 345 -884 -1,633 4
2020-12-31 82 -1,709 -1,558 2
2020-04-09
2019-12-31 0 -1,181 -1,311 4
DB:PH4 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-06-30 12 -699 -1,246
2019-03-31 12 -745 -858
2018-12-31 13 -791 -470
2018-09-30 13 -679 -336
2017-12-31 10 -240 -107
2016-12-31 -213 -117

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CStone Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CStone Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PH4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from CStone Pharmaceuticals Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PH4 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 -1.54 -1.28 -1.81 2.00
2021-12-31 -2.02 -1.96 -2.07 2.00
2020-12-31 -1.68 -1.18 -1.99 3.00
2020-04-09
2019-12-31 -1.30 -1.30 -1.30 1.00
DB:PH4 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-06-30 -2.72
2019-03-31 -2.74
2018-12-31 -2.79
2018-09-30 -2.06
2017-12-31 -0.67
2016-12-31 -0.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CStone Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess CStone Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CStone Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PH4 Past Performance

  How has CStone Pharmaceuticals performed over the past 5 years?

  • CStone Pharmaceuticals's last earnings update was 196 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CStone Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CStone Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare CStone Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CStone Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CStone Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CStone Pharmaceuticals Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PH4 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 11.54 -1,246.31 321.53 725.02
2019-03-31 12.04 -858.07 256.26 787.61
2018-12-31 12.55 -469.83 190.99 850.20
2018-09-30 13.03 -335.70 130.42 746.90
2017-12-31 10.30 -107.45 39.34 213.44
2016-12-31 -117.11 15.05 247.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CStone Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CStone Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CStone Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CStone Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CStone Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PH4 Health

 How is CStone Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CStone Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CStone Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CStone Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CStone Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.8274798448129E+18x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CStone Pharmaceuticals Company Filings, last reported 9 months ago.

DB:PH4 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 3,347.21 0.00 3,398.87
2019-03-31 3,347.21 0.00 3,398.87
2018-12-31 515.33 0.00 1,604.95
2018-09-30 1,082.26 0.00 1,714.14
2017-12-31 451.05 0.00 545.26
2016-12-31 766.96 0.00 811.93
  • CStone Pharmaceuticals's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if CStone Pharmaceuticals's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on CStone Pharmaceuticals's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess CStone Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CStone Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PH4 Dividends

 What is CStone Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CStone Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of CStone Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CStone Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CStone Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PH4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PH4 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2020-04-09
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CStone Pharmaceuticals has not reported any payouts.
  • Unable to verify if CStone Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CStone Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CStone Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of CStone Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess CStone Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CStone Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CStone Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PH4 Management

 What is the CEO of CStone Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Jiang
COMPENSATION CN¥141,294,000
AGE 58
TENURE AS CEO 3.8 years
CEO Bio

Dr. Frank Ningjun Jiang, MD, Ph.D., is Chairman of Board at CStone Pharmaceuticals since August 14, 2018 and has been Its Director since November 3, 2016. Dr. Jiang serves as Chief Executive Officer at CStone Pharmaceuticals Co., Ltd since July 2016. Prior to joining company, Dr. Jiang served as Head of Asia Pacific R&D with Sanofi China and led the R&D expansion efforts in the Asia & Pacific region. Dr. Jiang serves as the Chief Executive Officer at CStone Pharmaceuticals (Suzhou) Co., Ltd. Dr. Jiang was responsible for developing and implementing regional R&D strategies to develop innovative healthcare solutions and global drugs to Asia Pacific faster. During his tenure at Sanofi, he oversaw 79 clinical trials and obtained 30 New Drug Approvals in the Asia Pacific region. One of his career highlights at Sanofi was he headed an approximately 21,000-patient megatrial, which resulted in a successful global registration of a blockbuster drug Lovenox. Prior to Sanofi, Dr. Jiang served as clinical research physician with Eli Lilly, where he was a global phase II trial in suspected sepsis. Dr. Jiang is a U.S. board certified physician (Internal Medicine).

CEO Compensation
  • Frank's compensation has increased whilst company is loss making.
  • Frank's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the CStone Pharmaceuticals management team in years:

1.3
Average Tenure
  • The average tenure for the CStone Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Frank Jiang

TITLE
Chairman & CEO
COMPENSATION
CN¥141M
AGE
58
TENURE
3.8 yrs

Richard L. Yeh

TITLE
Chief Financial Officer
TENURE
1.8 yrs

Sanhu Wang

TITLE
Senior Vice President of Government Affairs
TENURE
0.8 yrs

Shirley Zhao

TITLE
GM of Greater China & Head of Commercial Operations
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure of the CStone Pharmaceuticals board of directors in years:

1.1
Average Tenure
  • The average tenure for the CStone Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Frank Jiang

TITLE
Chairman & CEO
COMPENSATION
CN¥141M
AGE
58
TENURE
1.7 yrs

Paul Bunn

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs

Elizabeth Jaffee

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs

Richard Finn

TITLE
Member of Scientific Advisory Board
TENURE
1.1 yrs

Weiping Zou

TITLE
Member of Scientific Advisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CStone Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CStone Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PH4 News

Simply Wall St News

PH4 Company Info

Description

CStone Pharmaceuticals, a clinical-stage biotechnology company, focuses on developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The company’s pre-clinical and late-stage clinical products include ivosidenib, a potent inhibitor of the mutated isocitrate dehydrogenase-1 enzyme for the treatment of cancer; CS1001, a momoclonal antibody against programmed death ligand-1; avapritinib, an inhibitor for the treatment of gastrointestinal stromal tumors and systematic mastocytosis; CS3009, an inhibitor for the treatment of non-small lung cancer and medullary thyroid carcinoma; CS3008 used for the treatment of hepatocellular carcinoma; CS1002, a monoclonal antibody for various indications; CS1003, a monoclonal antibody against programmed death receptor; and CS3006 for the treatment of solid tumors. Its products also comprise CS3002 and CS3003 for solid tumors, as well as CS3004, CS1009, CS3005, and CS2004 for other indications. In addition, the company provides medical and biotechnological development, technical consultation, technological transfer, and corporate management and commercial information consultation services. The company has a licensing agreement with Numab Therapeutics AG for the development and commercialization of ND021, a potential monovalent tri-specific antibody-based molecule targeting PD-L1, 4-1BB, and human serum albumin; and a clinical collaboration with Bayer HealthCare LLC to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib. CStone Pharmaceuticals was founded in 2015 and is headquartered in Shanghai, China.

Details
Name: CStone Pharmaceuticals
PH4
Exchange: DB
Founded: 2015
HK$992,216,140
1,028,817,603
Website: http://www.cstonepharma.com
Address: CStone Pharmaceuticals
Buillding 25,
1000 Zhangheng Road,
Shanghai,
201203,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 2616 Ordinary Shares The Stock Exchange of Hong Kong Ltd. HK HKD 26. Feb 2019
DB PH4 Ordinary Shares Deutsche Boerse AG DE EUR 26. Feb 2019
Number of employees
Current staff
Staff numbers
235
CStone Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:37
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2019/09/26
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.